Filtered By:
Specialty: Hematology
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 228 results found since Jan 2013.
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
ConclusionIn anticoagulated patients with AF the level of D‐dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D‐dimer level.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christina Christersson, Lars Wallentin, Ulrika Andersson, John H Alexander, Jack Ansell, Raffaele Caterina, Bernard J Gersh, Christopher B Granger, Michael Hanna, John D Horowitz, Kurt Huber, Steen Husted, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial.
CONCLUSION: In anticoagulated patients with AF the level of D-dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D-dimer level. This article is protected by copyright. All rights reserved.
PMID: 24942912 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A Tags: J Thromb Haemost Source Type: research
Oral anticoagulation and vitamin K deficiency.
Abstract
A 61-year old woman with atrial fibrillation developed macrohaematuria during anticoagulant treatment with a direct oral factor Xa inhibitor for stroke prevention. Abnormal results of coagulation assays were first interpreted as an effect of the anticoagulant. However, upon further testing diagnosis of vitamin K deficiency was established. After vitamin K supplementation, coagulation tests normalized and macrohaematuria disappeared. Treatment with broad spectrum antibiotics for urinary tract infection was finally established as a rare cause for vitamin K deficiency in the patient.
PMID: 24919584 [Pub...
Source: Hamostaseologie - June 12, 2014 Category: Hematology Authors: Eichinger S Tags: Hamostaseologie Source Type: research
Prothrombin Complex Concentrate (PCC) for Non‐Vitamin K Oral Anticoagulant (NOAC) reversal: Good enough for now?
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2014 Category: Hematology Authors: Mike Makris Tags: Commentary Source Type: research
Circulating desphospho-uncarboxylated matrix Gla protein and the risk of coronary heart disease and stroke.
CONCLUSION: The average follow-up was 11.5 years. Dp-ucMGP concentrations were not associated with CHD risk with a HR per SD of 1.00 (95% CI: 0.93-1.07) and a HR Q4 vs Q1 of 0.94 (95% CI: 0.79-1.13) after adjustment for cardiovascular risk factors. Dp-ucMGP was not associated with stroke risk (HRSD 0.98;95% CI: 0.90-1.08 and a HR Q4 vs Q1 of 1.09;95% CI: 0.78-1.51). This study could not confirm that high dp-ucMGP concentrations, reflecting a poor vitamin K status, are associated with increased CHD or stroke risk in the general population. This article is protected by copyright. All rights reserved.
PMID: 24826813 [Pub...
Source: Thrombosis and Haemostasis - May 15, 2014 Category: Hematology Authors: Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, Beulens JW Tags: J Thromb Haemost Source Type: research
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran
Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists. Dabigatran has been introduced into clinical practice, although issues like laboratory monitoring, its use in elderly patients, drug and food interactions, and an antidote have not been completely clarified. Severe epistaxis leading to haemorrhagic shock occurred in an 89-year-old woman with atrial fibrillation and moderate renal insufficiency after 10 months of dabigatran 110 mg/b.i.d. Correction of the anaemia with blood transfusions became dif...
Source: Blood Coagulation and Fibrinolysis - May 1, 2014 Category: Hematology Tags: Case Reports Source Type: research
Circulating desphospho‐uncarboxylated matrix Gla protein and the risk of coronary heart disease and stroke
This study could not confirm that high dp‐ucMGP concentrations, reflecting a poor vitamin K status, are associated with increased CHD or stroke risk in the general population.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 1, 2014 Category: Hematology Authors: Geertje W. Dalmeijer, Yvonne T. Schouw, Elke J. Magdeleyns, Cees Vermeer, W.M. Monique Verschuren, Jolanda M.A. Boer, Joline W.J. Beulens Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
This article is protected by copyright. All rights reserved.
PMID: 24597497 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: Harenberg J, Du S, Weiss C, Krämer R, Hoppensteadt D, Walenga J, The working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis Tags: J Thromb Haemost Source Type: research
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-AF study.
CONCLUSION: If anything, despite its early termination the idrabiotaparinux regimen studied suggested a comparable efficacy to dose-adjusted warfarin, with a lower bleeding risk. This article is protected by copyright. All rights reserved.
PMID: 24597472 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE Tags: J Thromb Haemost Source Type: research
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐AF study
ConclusionIf anything, despite its early termination the idrabiotaparinux regimen studied suggested a comparable efficacy to dose‐adjusted warfarin, with a lower bleeding risk.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: H.R. Buller, J. Halperin, G.J. Hankey, G. Pillion, M.H. Prins, G.E. Raskob Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Atrial fibrillation in patients with haemophilia: a cross‐sectional evaluation in Europe
Summary
Atrial fibrillation (AF) is a common health problem in the general population, but data on prevalence or management in patients with haemophilia (PWH) are lacking. The aims of this study were to analyse the prevalence of AF and risk factors for stroke using a cross‐sectional pan‐European design and to document current anticoagulation practice. The ADVANCE Working Group consists of members from 14 European haemophilia centres. Each centre retrieved data on their PWH with AF. From the total of 3952 adult PWH, 33 had AF with a mean age of 69 years (IQR 62–76). Haemophilia was severe in seven (21%), moderate in ...
Source: Haemophilia - March 1, 2014 Category: Hematology Authors: Roger E. G. Schutgens, R. Klamroth, I. Pabinger, M. Malerba, G. Dolan, Tags: Original Article Source Type: research
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Abstract
Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against ea...
Source: Thrombosis and Haemostasis - February 28, 2014 Category: Hematology Authors: Skjøth F, Larsen TB, Rasmussen LH, Lip GY Tags: Thromb Haemost Source Type: research
Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation.
The objectives of this review are to 1) identify gaps in our current knowledge regarding use of these single target anticoagulant drugs; 2) outline the potential implications of these gaps for clinical practice, and thereby, 3) highlight areas of research to further optimise their use for stroke prevention in AF.
PMID: 24573511 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 27, 2014 Category: Hematology Authors: Hylek EM, Ko D, Cove CL Tags: Thromb Haemost Source Type: research
Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
Vitamin K Antagonists (VKAs) are widely used in clinical practice and nearly 1% of the entire population receives oral anticoagulation at least once in life. However, the rate of prescription of anticoagulation is low, compared to what it should be. No more than 50-60% of patients affected by atrial fibrillation (AF) receive anticoagulation. In the setting of AF, VKAs are safe and effective when properly managed, reducing stroke and systemic embolism by more than 60%. VKAs safety and effectiveness are closely related to the quality of anticoagulation (e.g. time in therapeutic range), and anticoagulation clinics offer the b...
Source: Thrombosis Journal - February 18, 2014 Category: Hematology Authors: Mauro MolteniClaudio Cimminiello Source Type: research
Ensuring medication adherence with direct oral anticoagulant drugs: Lessons from adherence with vitamin K antagonists (VKAs)
Abstract: Medication adherence (taking drugs properly) is uncommon among patients on warfarin. Poor adherence to warfarin leads to an increase in adverse medical events, including stroke in atrial fibrillation (AF). Factors related to patients, physicians and the health system account for poor adherence. Direct oral anticoagulants (DOACs) are easier to use than warfarin, with fewer drug and food interactions and no need for routine blood monitoring. A proper use of DOACs may reduce the risk of stroke in AF. However, in clinical settings where no laboratory monitoring is needed, a poor medication adherence is common and may...
Source: Thrombosis Research - February 12, 2014 Category: Hematology Authors: Alessandro Di Minno, Gaia Spadarella, Antonella Tufano, Domenico Prisco, Giovanni Di Minno Tags: Mini-Reviews Source Type: research
